HARVARD BIOSCIENCE INC
HBIONASDAQ🏆 #3368 by market capEarnings Aug 11 · PreUS Equity
$6.13▼ $0.43 (−7.06%)
Live1h—
24h▼ 7.1%
7d▼ 3.8%
14d▲ 0.5%
30d▼ 7.2%
1y▲ 27.5%
🏦Market Cap
$28M
Small Cap
📈Revenue Growth (YoY)
-6.4%
Declining
📊Gross Margin
58.4%
Healthy
💵FCF Margin
8.0%
Moderate
⚖️P/S Ratio
0.3x
Cheap
Otter Score
54
Weak
Trading Snapshot
- Day Range
- $6.06 – $6.19
- 52-Week Range
- $3.75 – $9.40
- Volume
- $2.23B
- Avg Volume
- $1.89B
- Shares Outstanding
- 4.5M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $86M
- Last Q Revenue
- $21M
- P/E Ratio
- —
- P/S Ratio
- 0.3x
- EPS (TTM)
- $-2.20
- Dividend Yield
- —
Why Investors Own HBIO
- ✓High-growth profile — revenue up +47.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 50% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$86M▲ +43.2% YoY
Gross Margin (TTM)
49.8%▲ +2.5% YoY
Operating Income (TTM)
$28M▲ +43.2% YoY
Free Cash Flow (TTM)
$24M▲ +43.2% YoY
About HARVARD BIOSCIENCE INC
A company profile for HARVARD BIOSCIENCE INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
54/100
Analyst Price Target
ⓘAverage Target
$7.57
▲ +23.6% Upside
High Target$8.59
Low Target$6.70
Based on 13 analysts
Latest News & Updates
🚀
CNBC·2h ago
HARVARD BIOSCIENCE INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift HBIO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
HARVARD BIOSCIENCE INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.